Results 41 to 50 of about 11,499 (250)
Cardiovascular Diabetology, 2011 Background Progressive remodeling after myocardial infarction (MI) is a leading cause of morbidity and mortality. Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its short half ...
van Gilst Wiek H +4 more
doaj +1 more source
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. [PDF]
PLoS ONE, 2014 BACKGROUND: Obese-insulin resistance caused by long-term high-fat diet (HFD) consumption is associated with left ventricular (LV) dysfunction and increased risk of myocardial infarction.
Nattayaporn Apaijai +4 more
doaj +1 more source
Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. [PDF]
, 2014 peer reviewedPatients with type 2 diabetes mellitus have an increased risk of chronic liver disease (CLD) such as non-alcoholic fatty liver disease and steatohepatitis, and about one-third of cirrhotic patients have diabetes.
Scheen, André
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson +4 more
wiley +1 more source
JIIS: Jurnal Ilmiah Ibnu Sina, 2023 Metformin sebagai terapi Diabetes Melitus (DM) lini pertama, yang belum mampu mengontrol glukosa darah pada DM tipe 2. Salah satu golongan Dipeptidyl Peptidase IV Inhibitor (DPP4-I), yakni vildagliptin telah masuk dalam Formularium Nasional yang ...
Dwi Octamy Sari +3 more
doaj +1 more source
Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice -- study rationale and protocol of DIALOGUE [PDF]
, 2012 BACKGROUND: Patients with type 2 diabetes have 2–4 times greater risk for cardiovascular morbidity and mortality than those without, and this is even further aggravated if they also suffer from hypertension.
Anselm K Gitt +5 more
core +2 more sources
Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries
British Journal of Pharmacology, EarlyView.Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley +1 more source
Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man
Frontiers in Endocrinology, 2019 Vildagliptin blocks glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) inactivation of the meal induced increases in GLP-1 and GIP so that elevated GLP-1 and GIP levels are maintained over 24 h.
James E. Foley
doaj +1 more source
Diabetic Medicine, EarlyView.Abstract Introduction Type 2 diabetes is a complex condition with a multifactorial pathogenesis. The pathogenesis is considered to be polygenic due to complex interactions between genetic/epigenetic and environmental factors. The aim of this study is to determine the genetic, environmental and lifestyle factors associated with the development of type 2
Sunny Chinenye +18 more
wiley +1 more source